Autoimmune disease prevalence is fueling the Remicade Market 2026

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Size Expansion Is Predicted For The Remicade Market Between 2026 And 2030?

The remicade market size has shown strong expansion in recent years. It is anticipated to grow from $2656.87 million in 2025 to $2803.31 million in 2026, exhibiting a compound annual growth rate (CAGR) of 5.5%. The expansion witnessed during the historic period can be attributed to the rising prevalence of autoimmune disorders, broader clinical acceptance of biologics, the proliferation of hospital infusion centers, enhanced diagnosis of inflammatory diseases, and the growth in specialty pharmaceutical distribution.

The remicade market size is projected to experience robust expansion over the next few years. It is expected to reach $3433.68 million by 2030, driven by a compound annual growth rate (CAGR) of 5.2%. The anticipated growth during the forecast period is fueled by several factors, including the increasing demand for biosimilar competition, rising investments in biologics manufacturing, the expansion of home infusion care models, a growing focus on personalized autoimmune therapies, and advancements in monoclonal antibody development. Key trends influencing the market in this period involve the increasing use of TNF-alpha inhibitor therapies, the rising adoption of biologic treatments for autoimmune diseases, a growing preference for long-term disease control drugs, the expansion of specialty infusion services, and an enhanced focus on patient-centered treatment outcomes.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20194&type=smp

What Drivers Are Influencing The Remicade Market?

The increasing occurrence of autoimmune diseases is expected to boost the growth of the remicade market in the future. Autoimmune conditions are characterized by the immune system mistakenly attacking the body’s own healthy cells, tissues, or organs, perceiving them as foreign threats. The rise in autoimmune disease cases can be attributed to a combination of genetic predispositions, environmental changes, increased exposure to pollutants, lifestyle choices, and enhanced diagnostic awareness. Remicade (infliximab) is utilized to manage autoimmune diseases by targeting and inhibiting tumor necrosis factor-alpha (TNF-a), a crucial inflammatory cytokine involved in conditions such as rheumatoid arthritis, Crohn’s disease, and ulcerative colitis. For instance, in April 2025, GOV.UK, a UK-based government public health agency, stated that in 2024, the prevalence of people aged 16 and over self-reporting a long-term musculoskeletal (MSK) condition was 17.9%, with females (20.0%) demonstrating a higher incidence compared to males (15.6%). Therefore, the escalating incidence of autoimmune diseases fuels the remicade market.

Which Market Segments Are Examined In The Remicade Market Study?

The remicade market covered in this report is segmented –

1) By Disease Indication: Crohn’s disease, Rheumatoid arthritis, Ankylosing spondylitis, Psoriatic arthritis, Ulcerative Colitis, Plaque psoriasis

2) By Route Of Administration: Subcutaneous, Intravenous, Parenteral

3) By End Use: Hospitals, Clinics, Ambulatory Care, Home Care

Which Trends Are Influencing The Remicade Market?

Leading companies in the Remicade (infliximab) market are concentrating on developing innovative solutions, including subcutaneous formulations of biologic therapies, to meet the increasing demand for greater patient convenience, improved treatment adherence, and more time-efficient alternatives to traditional intravenous dosing. Subcutaneous biologics enable patients to self-administer maintenance doses at home, consequently reducing infusion-center visits and providing a more accessible option compared to conventional IV formulations. For example, in March 2024, Celltrion USA, Inc., a US-based biopharmaceutical company, launched Zymfentra (infliximab-dyyb), which is the first FDA-approved subcutaneous formulation of infliximab. Zymfentra is prescribed as maintenance therapy for adults with moderate-to-severe active ulcerative colitis (UC) and Crohn’s disease (CD), collectively referred to as inflammatory bowel disease (IBD). Approved for use subsequent to IV induction with an infliximab product, it offers a convenient, self-administered choice for long-term disease management.

Who Are The Primary Competitors In The Remicade Market?

Major companies operating in the remicade market are Janssen Biotech Inc.

Read the full remicade market report here:

https://www.thebusinessresearchcompany.com/report/remicade-global-market-report

Which Regions Are Expected To Experience Rapid Expansion In The Remicade Market?

North America was the largest region in the remicade market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the remicade market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Remicade Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=20194&type=smp

Browse Through More Reports Similar to the Global Remicade Market 2026, By The Business Research Company

Remicade Biosimilar Market Report 2026

https://www.thebusinessresearchcompany.com/report/remicade-biosimilar-global-market-report

Biopreservation Market Report 2026

https://www.thebusinessresearchcompany.com/report/biopreservation-global-market-report

Bevacizumab Biosimilars Market Report 2026

https://www.thebusinessresearchcompany.com/report/bevacizumab-biosimilars-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795